7 days ago
BBIO
AnalystsDanielle BrillDanielle Brill's Stock Forecasts
AnalystsDanielle Brill
Analyst Ranking
Top 15%
#756 out of 5206 analysts
Average Return
+12.37%
Win Rate
46%42 out of 92
Risk vs Reward
Poor
Good
Danielle Brill's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Uniqure NvQURE | +1,074.35% | $5.42 | $63.65 | 2024-10-10 - 2025-10-09 | Buy |
Palvella Therapeutics IncPVLA | +327.77% | $31.00 | $132.61 | 2025-07-21 - 2026-03-02 | Strong Buy |
Sage Therapeutics IncSAGE | +149.76% | $70.20 | $175.33 | 2017-05-16 - 2018-05-16 | Buy |
Palvella Therapeutics IncPVLA | +111.74% | $62.63 | $132.61 | 2025-10-02 - 2026-03-02 | Strong Buy |
Argenx SeARGX | +76.16% | $354.13 | $623.82 | 2023-12-21 - 2024-12-20 | Strong Buy |
Danielle Brill Analyst Color
Get additional color on Danielle Brill's coverage of popular stocks
15 days ago
NBIX
a month ago
CNTA
2 months ago
ARGX
2 months ago
NBIX
2 months ago
DNTH
2 months ago
CNTA
2 months ago
BBIO
3 months ago
PVLA
4 months ago
IRON
4 months ago
BBIO
5 months ago
ALNY
5 months ago
PVLA
a year ago
SRPT
Danielle Brill's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Disc Medicine IncIRON | 7 | Strong Buy | $83.00 | +24.74% | Maintains | 5 days ago |
Bridgebio Pharma IncBBIO | 4 | Strong Buy | $95.00 | +45.04% | Maintains | 7 days ago |
Neurocrine Biosciences IncNBIX | 9 | Strong Buy | $140.00 | +5.76% | Maintains | 15 days ago |
Centessa Pharmaceuticals PLCCNTA | 3 | Strong Buy | $38.00 | +43.34% | Maintains | a month ago |
Argenx SeARGX | 8 | Strong Buy | $1,030.00 | +36.11% | Maintains | 2 months ago |
Tectonic Therapeutic IncTECX | 3 | Strong Buy | $60.00 | +160.87% | Maintains | 2 months ago |
Immunovant IncIMVT | 6 | Hold | $22.00 | -20.72% | Maintains | 2 months ago |
Harmony Biosciences Holdings IncHRMY | 9 | Strong Buy | $45.00 | +55.71% | Maintains | 2 months ago |
Dianthus Therapeutics IncDNTH | 2 | Strong Buy | $63.00 | +14.01% | Maintains | 2 months ago |
Alnylam Pharmaceuticals IncALNY | 3 | Strong Buy | $530.00 | +63.04% | Maintains | 2 months ago |
Palvella Therapeutics IncPVLA | 4 | Strong Buy | $190.00 | +43.28% | Maintains | 3 months ago |
Upstream Bio IncUPB | 1 | Strong Buy | $47.00 | +510.39% | Initiates Coverage On | 5 months ago |
Jefferson Capital IncJCAP | 1 | Strong Buy | $24.00 | +15.83% | Initiates Coverage On | 7 months ago |
Uniqure NvQURE | 6 | Strong Buy | $52.00 | N/A | Upgrades | a year ago |
Biomarin Pharmaceutical IncBMRN | 1 | Buy | $79.00 | N/A | Reinstates | a year ago |
Regenxbio IncRGNX | 1 | Buy | $18.00 | N/A | Reinstates | a year ago |
Sarepta Therapeutics IncSRPT | 2 | Buy | $150.00 | N/A | Reinstates | a year ago |
Xenon Pharmaceuticals IncXENE | 2 | Buy | $50.00 | N/A | Reinstates | a year ago |
Agios Pharmaceuticals IncAGIO | 2 | Buy | $51.00 | N/A | Reinstates | a year ago |
Biogen IncBIIB | 1 | Buy | $283.00 | N/A | Upgrades | 2 years ago |
Passage Bio IncPASG | 5 | Buy | $100.00 | N/A | Maintains | 2 years ago |
Ptc Therapeutics IncPTCT | 6 | Buy | $55.00 | N/A | Maintains | 3 years ago |
Kyntra Bio IncKYNB | 2 | Buy | $875.00 | N/A | Upgrades | 3 years ago |
Acceleron Pharma IncXLRN | 2 | Hold | N/A | N/A | Downgrades | 4 years ago |
Vertex Pharmaceuticals IncVRTX | 1 | Hold | N/A | N/A | Initiates Coverage On | 5 years ago |
Acadia Pharmaceuticals IncACAD | 2 | Buy | $35.00 | N/A | Downgrades | 5 years ago |
Global Blood Therapeutics IncGBT | 4 | Hold | $50.00 | N/A | Downgrades | 5 years ago |
Gw Pharmaceuticals PLCGWPH | 1 | Hold | N/A | N/A | Initiates Coverage On | 6 years ago |
Zogenix IncZGNX | 1 | Hold | N/A | N/A | Initiates Coverage On | 6 years ago |
Alder Biopharmaceuticals IncALDR | 2 | Buy | $28.00 | N/A | Assumes | 8 years ago |
Sage Therapeutics IncSAGE | 1 | Buy | $82.00 | N/A | Initiates Coverage On | 9 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.